AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11220420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium for both intubation and maintenance (Group PP)
Number of subjects: 78
Study 11220420 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium for intubation followed by pancuronium for maintenance (Group RP)
Number of subjects: 78
Study 11220420 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium for both doses (Group PP)
Number of subjects: 78
Study 9433370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg
Number of subjects: 99
Study 9433370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg
Number of subjects: 99
Study 9433370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 7950181 — intervention group
Group type: EXPERIMENTAL
Intervention: No. 90 Dasheng Jiangya (DSJY) oral liquid
Number of subjects: 109
Study 7950181 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 109
Study 3307992 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted closure with polyglactin
Number of subjects: 1491
Study 3307992 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous closure with polyglactin
Number of subjects: 1491
Study 3307992 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous closure with polydioxanone
Number of subjects: 1491
Study 3307992 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous closure with nylon
Number of subjects: 1491
Study 3307992 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1491
Study 29879469 — intervention group
Group type: EXPERIMENTAL
Intervention: HoPS+ (Homens para Saúde Mais) intervention
Number of subjects: 1080
Study 29879469 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1080
Study 27065308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education (NEd) using Health Belief Model (HBM), provided twice monthly for 6 months to the intervention group (n = 80)
Number of subjects: 160
Study 27065308 — intervention group
Group type: COMPARATOR
Intervention: Usual education for control mothers
Number of subjects: 160
Study 27065308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education (NEd) using Health Belief Model (HBM)
Number of subjects: 160
Study 25057076 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified right ventricular outflow tract pacing (MRVOTP)
Number of subjects: 136
Study 25057076 — intervention group
Group type: COMPARATOR
Intervention: Conventional right ventricular outflow tract pacing (CRVOTP)
Number of subjects: 136
Study 22961605 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AC) administered in 20 sessions over 10 weeks
Number of subjects: 69
Study 22961605 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanacetum (TAN) at 150 mg/day
Number of subjects: 69
Study 22961605 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (AC+TAN)
Number of subjects: 69
Study 20400483 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider initiated primary care outreach intervention
Number of subjects: 719
Study 20400483 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 719
Study 19011431 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-101,606
Number of subjects: 30
Study 19011431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16167916 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day)
Number of subjects: 39
Study 16167916 — intervention group
Group type: COMPARATOR
Intervention: Calcium (500 mg/day)
Number of subjects: 39
Study 12763376 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (100 mg) for 52 weeks
Number of subjects: 238
Study 12763376 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine plus interferon for 24 weeks
Number of subjects: 238
Study 12763376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 10690862 — intervention group
Group type: EXPERIMENTAL
Intervention: 20K-hGH
Number of subjects: 6
Study 10690862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8843176 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 60 mg twice per day
Number of subjects: 42
Study 8843176 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once per day
Number of subjects: 42
Study 1321894 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose chemotherapy (50% dose reduction of all chemotherapeutic agents)
Number of subjects: 256
Study 1321894 — intervention group
Group type: COMPARATOR
Intervention: Full-dose chemotherapy (in older children)
Number of subjects: 256
Study 6360295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol
Number of subjects: 21
Study 6360295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30626611 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP(3‐30)NH2 plus exendin(9‐39)NH2
Number of subjects: 18
Study 30626611 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP(3‐30)NH2
Number of subjects: 18
Study 30626611 — intervention group
Group type: EXPERIMENTAL
Intervention: exendin(9‐39)NH2
Number of subjects: 18
Study 30626611 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 18
Study 30335579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water immersion (HWI) at 39°C for 1 hour
Number of subjects: 10
Study 30335579 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 hot water immersion sessions (INT) over 2 weeks
Number of subjects: 10
Study 30335579 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 10
Study 27778457 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital 12-lead Holter ECG
Number of subjects: 34
Study 27778457 — intervention group
Group type: COMPARATOR
Intervention: Standard ECG
Number of subjects: 34
Study 27778457 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter ECG
Number of subjects: 34
Study 24810491 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (starting after 2 weeks of tuberculosis treatment)
Number of subjects: 1675
Study 24810491 — intervention group
Group type: COMPARATOR
Intervention: Delayed ART (placebo, then starting ART at the end of 6 months of tuberculosis treatment)
Number of subjects: 1675
Study 24810491 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (CD4 count 220-349 cells per μL)
Number of subjects: 1675
Study 24810491 — intervention group
Group type: COMPARATOR
Intervention: Delayed ART (CD4 count 220-349 cells per μL)
Number of subjects: 1675
Study 24810491 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (CD4 count 350 cells per μL or more)
Number of subjects: 1675
Study 24810491 — intervention group
Group type: COMPARATOR
Intervention: Delayed ART (CD4 count 350 cells per μL or more)
Number of subjects: 1675
Study 24810491 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 1675
Study 21822762 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training (PT) added to antipsychotic medication
Number of subjects: 0
Study 21822762 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication plus PT
Number of subjects: 0
Study 19200788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 0
Study 19200788 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (dexamethasone)
Number of subjects: 0
Study 19200788 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17972062 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive total knee arthroplasty with computer-assisted navigation
Number of subjects: 0
Study 17972062 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 0
Study 15108570 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention consisting of six calls over eight weeks discussing safety-promoting behaviors.
Number of subjects: 150
Study 15108570 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 150
Study 11803730 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg/day
Number of subjects: 1061
Study 11803730 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 1061
Study 11803730 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day
Number of subjects: 1061
Study 11803730 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg/day
Number of subjects: 1061
Study 11803730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study 9667265 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiation therapy starting on day 1 of chemotherapy (arm I)
Number of subjects: 399
Study 9667265 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiation therapy starting on day 64 of chemotherapy (arm II)
Number of subjects: 399
Study 9667265 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (arm III)
Number of subjects: 399
Study 7830803 — intervention group
Group type: EXPERIMENTAL
Intervention: New biscuit (25 biscuits of 15.5 g each in 2 weeks)
Number of subjects: 10
Study 2974715 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg day‐1)
Number of subjects: 6
Study 2974715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg day‐1)
Number of subjects: 6
Study 2974715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cilazapril and propranolol
Number of subjects: 6
Study 2974715 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 2974715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 6
Study 2974715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of cilazapril and propranolol
Number of subjects: 6
Study 2974715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29490031 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1700 or 2000 mg/d
Number of subjects: 182
Study 29490031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 27655517 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral health care (POHC) and Mucosamin® during recovery after transplantation
Number of subjects: 68
Study 27655517 — intervention group
Group type: COMPARATOR
Intervention: Clorexidine 0.20% (control)
Number of subjects: 68
Study 24491034 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Outlook online self-management program (90 minutes per week for 7 weeks)
Number of subjects: 0
Study 24491034 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study 22794117 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol
Number of subjects: 0
Study 22794117 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 0
Study 20829713 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (O) 10 mg once-daily, with possible dose increase to 40 mg
Number of subjects: 1102
Study 20829713 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (R) 2.5 mg once-daily, with possible dose increase to 10 mg
Number of subjects: 1102
Study 20829713 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (O)
Number of subjects: 1102
Study 20829713 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (R)
Number of subjects: 1102
Study 18533736 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination therapy with statins (e.g., niacin/lovastatin, ezetimibe/simvastatin, amlodipine/atorvastatin)
Number of subjects: 0
Study 18533736 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin/pravastatin
Number of subjects: 0
Study 15919088 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 microg of rectal misoprostol administered by traditional birth attendants (TBAs) in the intervention area.
Number of subjects: 849
Study 15919088 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (no misoprostol treatment, referred to nearest facility).
Number of subjects: 849
Study 14655926 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-mg slow-release melatonin
Number of subjects: 157
Study 14655926 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg melatonin
Number of subjects: 157
Study 14655926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 11018193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily
Number of subjects: 221
Study 11018193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 9011975 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 707
Study 9011975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study 1639636 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) at 12 Gy
Number of subjects: 36
Study 1639636 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) at 14 Gy
Number of subjects: 36
Study 1639636 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) at 16 Gy
Number of subjects: 36
Study 1639636 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) at 17 Gy
Number of subjects: 36
Study 1639636 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival post-transplant
Number of subjects: 36
Study 1639636 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse rate post-transplant
Number of subjects: 36
Study 6144462 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 0.5 mg
Number of subjects: 12
Study 6144462 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 1.0 mg
Number of subjects: 12
Study 6144462 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2.0 mg
Number of subjects: 12
Study 6144462 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5.0 mg
Number of subjects: 12
Study 6144462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (various doses)
Number of subjects: 12
Study 6144462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 12
Study 28810425 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-focused campaigns
Number of subjects: 0
Study 28810425 — intervention group
Group type: COMPARATOR
Intervention: Weight-neutral campaigns
Number of subjects: 0
Study 30276500 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 1622
Study 30276500 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 1622
Study 30276500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1622
Study 30276500 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg (CM)
Number of subjects: 1622
Study 30276500 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg (CM)
Number of subjects: 1622
Study 26271677 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 adult-METs
Number of subjects: 102
Study 26271677 — intervention group
Group type: COMPARATOR
Intervention: 1.5 adult-METs
Number of subjects: 102
Study 26271677 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 child-METs
Number of subjects: 102
Study 24795503 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (VSL#3)
Number of subjects: 60
Study 24795503 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Number of subjects: 60
Study 24795503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both omega-3 and probiotic (VSL#3)
Number of subjects: 60
Study 24795503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22474401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine-telmisartan combination treatment
Number of subjects: 0
Study 21313903 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine + ketamine (5 mg pethidine and 0.25 mg kg(‐1) ketamine)
Number of subjects: 100
Study 21313903 — intervention group
Group type: COMPARATOR
Intervention: pethidine + placebo (10 mg pethidine and NS)
Number of subjects: 100
Study 21313903 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine + ketamine
Number of subjects: 100
Study 21313903 — intervention group
Group type: COMPARATOR
Intervention: pethidine + placebo
Number of subjects: 100
Study 18037745 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic Doppler echocardiography with intravenous administration of adenosine (0.16 mg.kg(‐1).min(‐1))
Number of subjects: 32
Study 18037745 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic Doppler echocardiography
Number of subjects: 32
Study 16229850 — intervention group
Group type: EXPERIMENTAL
Intervention: Y402H polymorphism
Number of subjects: 685
Study 16229850 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma C-reactive protein levels
Number of subjects: 685
Study 12823878 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a cervical orthosis (neck brace) during the first drive (Group A)
Number of subjects: 23
Study 12823878 — intervention group
Group type: COMPARATOR
Intervention: Not wearing a cervical orthosis during the first drive (Group B)
Number of subjects: 23
Study 12823878 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a cervical orthosis (neck brace) during the second drive (Group B)
Number of subjects: 23
Study 12823878 — intervention group
Group type: COMPARATOR
Intervention: Not wearing a cervical orthosis during the second drive (Group A)
Number of subjects: 23
Study 11111290 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO) in addition to relief of weightbearing structures (Gr. II)
Number of subjects: 20
Study 11111290 — intervention group
Group type: COMPARATOR
Intervention: Relief of weightbearing structures only (Gr. I)
Number of subjects: 20
Study 8868017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate regimen
Number of subjects: 0
Study 8868017 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular magnesium sulfate regimen
Number of subjects: 0
Study 1299709 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A, standard dosage of clofazimine (CLO) in multidrug therapy (MDT) regimen
Number of subjects: 45
Study 1299709 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B, CLO 600 mg once every 4 weeks
Number of subjects: 45
Study 1299709 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C, CLO 1200 mg once every 4 weeks
Number of subjects: 45
Study 6608419 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium cardioplegic solutions with added blood (group B)
Number of subjects: 60
Study 6608419 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid potassium cardioplegics (group C)
Number of subjects: 60
Study 31951305 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval exercise
Number of subjects: 0
Study 30628813 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg for five days)
Number of subjects: 31
Study 30628813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for five days)
Number of subjects: 31
Study 27794196 — intervention group
Group type: EXPERIMENTAL
Intervention: One apple (low consumption)
Number of subjects: 30
Study 27794196 — intervention group
Group type: EXPERIMENTAL
Intervention: Two apples (medium consumption)
Number of subjects: 30
Study 27794196 — intervention group
Group type: EXPERIMENTAL
Intervention: Four apples (high consumption)
Number of subjects: 30
Study 27794196 — intervention group
Group type: COMPARATOR
Intervention: Control (abstaining from apples)
Number of subjects: 30
Study 26391511 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy with weekly mobile phone messages for three months
Number of subjects: 144
Study 26391511 — intervention group
Group type: COMPARATOR
Intervention: Post-HIV test counselling
Number of subjects: 144
Study 23393209 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 432
Study 23393209 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 432
Study 21529848 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 880
Study 21529848 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 880
Study 18336488 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online teaching modules and simulated critical incident scenarios
Number of subjects: 0
Study 18336488 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated scenario supplemented by online teaching
Number of subjects: 0
Study 18336488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive drug administration teaching using an online module and high fidelity simulation
Number of subjects: 0
Study 18336488 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation
Number of subjects: 0
Study 18336488 — intervention group
Group type: COMPARATOR
Intervention: Poor simulator score
Number of subjects: 0
Study 16520042 — intervention group
Group type: EXPERIMENTAL
Intervention: Automode ventilation (group A, n = 10)
Number of subjects: 20
Study 16520042 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (group B, n = 10)
Number of subjects: 20
Study 16520042 — intervention group
Group type: EXPERIMENTAL
Intervention: Automode ventilation (group A)
Number of subjects: 20
Study 16520042 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (group B)
Number of subjects: 20
Study 14579065 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits by a specially trained nurse
Number of subjects: 77
Study 14579065 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and assessment
Number of subjects: 77
Study 10699339 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent cold-adapted influenza vaccine
Number of subjects: 10
Study 10699339 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural immunity from influenza A infection in year 1
Number of subjects: 10
Study 10699339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9200764 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomepromazine (50 mg/day)
Number of subjects: 26
Study 9200764 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine (50 mg/day)
Number of subjects: 26